SCHEMBL5117230

SCHEMBL5117230

O=C(O)NCCc1cccc(F)c1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.59
TAAR1 Q96RJ0 3/20 0.59
TP53 P04637 1/20 0.57
LMNA P02545 2/20 0.52
ALDH1A1 P00352 1/20 0.52
MAPT P10636 1/20 0.52
POLB P06746 1/20 0.52
THRB P10828 1/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
OPRM1 P35372 2/20 0.49
OPRD1 P41143 1/20 0.49
OPRK1 P41145 1/20 0.49
OPRL1 P41146 1/20 0.49
NAMPT P43490 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5554486 0.88 TAAR1 (0.50) CNR1TAAR1TP53
SCHEMBL28872233 0.87 CNR1 (0.57) CNR1TAAR1TP53LMNAALDH1A1
SCHEMBL30016330 0.87 CNR1 (0.57) CNR1TAAR1TP53LMNAALDH1A1
SCHEMBL27895492 0.86 NR4A2 (0.62)
SCHEMBL1010528 0.85 TAAR1 (0.62) CNR1TAAR1TP53LMNAALDH1A1
SCHEMBL8802955 0.84 ALDH1A1 (0.69) CNR1TAAR1TP53LMNAALDH1A1
SCHEMBL23973860 0.83 CNR1 (0.60) CNR1TAAR1TP53LMNAALDH1A1
SCHEMBL29699631 0.82 SRC (0.61) TP53ALDH1A1POLBRAB9A
SCHEMBL3109722 0.82 SRC (0.61) TP53ALDH1A1POLBRAB9A
SCHEMBL14241863 0.82 MTNR1A (0.67) CNR1TAAR1TP53OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1894217-B Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors HOFFMANN LA ROCHE 2011-09-21 CN disclosed
US-20080108814-A1 Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-05-08 US disclosed
CN-1894217-A Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors HOFFMANN LA ROCHE (CH) 2007-01-10 CN disclosed
EP-1673347-A1 SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS F. Hoffman-la Roche AG (CH) 2006-06-28 EP disclosed
WO-2005040126-A1 SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS F. HOFFMAN-LA ROCHE AG (CH) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108814-A1 Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase NOS1, NOS2, NOS3 CNR1 2388/4885TAAR1 1066/4885TP53 2008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.